Cefoperazone is indicated for the treatment of infections caused by susceptible organisms, including respiratory tract infections, peritonitis and other intra-abdominal infections, bacterial septicemia, skin and skin structure infections, pelvic inflammatory disease, endometritis and other infections of the female genital tract, urinary tract infections, and enterococcal infections.

Cefoperazone is a bactericidal cephalosporin antibiotic that is resistant to most β-lactamases and is active against a broad spectrum of aerobic and anaerobic, Gram-positive and Gram-negative bacteria. Its bactericidal effect occurs through inhibition of bacterial cell wall synthesis. Cefoperazone demonstrates high stability against β-lactamases produced by many Gram-negative organisms and is often effective against bacteria resistant to other β-lactam antibiotics.

Sterile Cefoperazone Sodium can be administered by IM or IV injection (following dilution).

Adult: 2 to 4 grams per day administered in equally divided doses every 12 hours. In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6-12 grams divided into 2,3, or 4 administrations ranging from 1.5 to 4 grams per dose. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.

Cefoperazone is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics.

Hypersensitivity reactions may occur, including skin reactions, drug fever, and changes in Coombs’ test results. These reactions are more likely in patients with a history of allergies, particularly to penicillin.

Cefoperazone is classified as pregnancy category B and should be used during pregnancy only if clearly necessary. Only small amounts are excreted into human breast milk. Although its transfer into breast milk is minimal, caution is advised when administered to nursing mothers.

Cefoperazone is primarily excreted in bile, and its half-life may be prolonged in patients with hepatic disease or biliary obstruction. In such patients, total daily doses above 4 g are generally not required. If higher doses are used, serum drug levels should be monitored carefully.

Children use: Safety and effectiveness in pediatric patients have not been established.

Geriatric use: Clinical experience has not shown significant differences in response between elderly and younger patients; however, dose selection should be cautious, considering possible reduced hepatic, renal, or cardiac function and concomitant disease or therapy.

Third generation Cephalosporins

Store in a dry place below 25°C and protect from light before reconstitution. After reconstitution, the solution may be stored for up to 24 hours at room temperature (below 25°C).